PriceTargets.com logo

Novo Nordisk A/S - NVO Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $56.00
  • Forecasted Upside: 16.69%
  • Number of Analysts: 21
  • Breakdown:
  • 2 Sell Ratings
  • 12 Hold Ratings
  • 6 Buy Ratings
  • 1 Strong Buy Ratings
$47.99 As of 12/4/2025 04:59 PM ET
▲ +0.42 (0.88%)

This chart shows the closing price for NVO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Novo Nordisk A/S Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NVO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NVO

Analyst Price Target is $56.00
▲ +16.69% Upside Potential
This price target is based on 21 analysts offering 12 month price targets for Novo Nordisk A/S in the last 3 months. The average price target is $56.00, with a high forecast of $70.00 and a low forecast of $42.00. The average price target represents a 16.69% upside from the last price of $47.99.

This chart shows the closing price for NVO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 21 polled investment analysts is to hold stock in Novo Nordisk A/S. This rating has held steady since October 2025, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 1 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 2 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 12 hold ratings
  • 1 sell ratings
Ratings as of
9/5/2025
  • 2 strong buy ratings
  • 7 buy ratings
  • 10 hold ratings
  • 2 sell ratings
Ratings as of
11/4/2025
  • 1 strong buy ratings
  • 6 buy ratings
  • 12 hold ratings
  • 2 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 1 strong buy ratings
  • 6 buy ratings
  • 12 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/3/2025Morgan StanleyReiterated RatingUnderweight ➝ Underweight$42.00
12/1/2025Weiss RatingsReiterated RatingHold (C-) ➝ Hold (C-)
11/28/2025The Goldman Sachs GroupLower TargetBuy ➝ Buy$60.00 ➝ $54.00
11/25/2025BMO Capital MarketsLower TargetMarket Perform ➝ Market Perform$50.00 ➝ $46.00
11/24/2025Weiss RatingsUpgradeSell (D+) ➝ Hold (C-)
11/24/2025Hsbc Global ResDowngradeStrong-Buy ➝ Hold
11/24/2025HSBCDowngradeBuy ➝ Hold
11/17/2025Weiss RatingsReiterated RatingSell (D+) ➝ Sell (D+)
11/17/2025BMO Capital MarketsReiterated RatingMarket Perform ➝ Market Perform
11/11/2025Weiss RatingsReiterated RatingSell (D+) ➝ Sell (D+)
11/5/2025Weiss RatingsDowngradeHold (C-) ➝ Sell (D+)
10/27/2025Jefferies Financial GroupInitiated CoverageUnderperform ➝ Underperform
10/14/2025BMO Capital MarketsReiterated RatingMarket Perform ➝ Market Perform$50.00 ➝ $55.00
10/14/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
10/1/2025HSBCSet Target$70.00
10/1/2025Hsbc Global ResUpgradeHold ➝ Strong-Buy
10/1/2025HSBCUpgradeHold ➝ Buy$70.00
9/29/2025Morgan StanleyDowngradeOverweight ➝ Underweight$59.00 ➝ $47.00
9/29/2025Zacks ResearchUpgradeStrong Sell ➝ Hold
9/27/2025Weiss RatingsReiterated RatingHold (C-) ➝ Hold (C-)
9/17/2025Berenberg BankUpgradeHold ➝ Buy
9/16/2025Rothschild RedbUpgradeHold ➝ Strong-Buy
9/16/2025Rothschild & Co RedburnUpgradeNeutral ➝ Buy
9/9/2025Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform
8/22/2025Dbs BankUpgradeStrong Sell ➝ Hold
8/20/2025Zacks ResearchDowngradeHold ➝ Strong Sell
8/19/2025TD CowenLower TargetBuy ➝ Buy$105.00 ➝ $70.00
8/13/2025BNP ParibasUpgradeUnderperform ➝ Neutral
8/13/2025BNP Paribas ExaneUpgradeUnderperform ➝ Neutral$54.00
8/5/2025UBS GroupDowngradeBuy ➝ Neutral
7/31/2025Hsbc Global ResDowngradeStrong-Buy ➝ Hold
7/31/2025HSBCDowngradeBuy ➝ Hold$57.00
7/30/2025BarclaysReiterated RatingOverweight ➝ Equal Weight
4/28/2025Hsbc Global ResUpgradeStrong-Buy
4/25/2025Dbs BankDowngradeSell
4/17/2025GuggenheimDowngradeStrong-Buy ➝ Hold
4/17/2025BMO Capital MarketsReiterated RatingOutperform ➝ Market Perform$105.00 ➝ $64.00
4/15/2025BNP ParibasInitiated CoverageStrong-Buy ➝ Underperform
3/13/2025Kepler Capital MarketsUpgradeHold ➝ Buy
3/3/2025Stifel NicolausDowngradeBuy ➝ Hold
2/12/2025Morgan StanleyInitiated CoverageEqual Weight
1/8/2025UBS GroupUpgradeSell ➝ Buy
1/6/2025Sanford C. BernsteinUpgradeUnderperform ➝ Market Perform
12/23/2024BMO Capital MarketsLower TargetOutperform ➝ Outperform$156.00 ➝ $105.00
12/2/2024BNP ParibasUpgradeStrong-Buy
11/6/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00 ➝ $160.00
10/17/2024BMO Capital MarketsLower TargetOutperform ➝ Outperform$160.00 ➝ $156.00
10/10/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00 ➝ $160.00
9/16/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00 ➝ $160.00
9/9/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00 ➝ $160.00
8/19/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00 ➝ $160.00
8/8/2024BMO Capital MarketsLower TargetOutperform ➝ Outperform$170.00 ➝ $160.00
8/5/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00 ➝ $160.00
7/1/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00 ➝ $160.00
6/25/2024BMO Capital MarketsReiterated RatingOutperform ➝ Outperform$163.00 ➝ $163.00
6/17/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00 ➝ $160.00
6/10/2024ArgusBoost TargetBuy ➝ Buy$125.00 ➝ $160.00
5/30/2024The Goldman Sachs GroupInitiated CoverageBuy$156.00
4/18/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00
4/12/2024BMO Capital MarketsInitiated CoverageOutperform$163.00
4/1/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00
3/20/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00
2/20/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$140.00
2/14/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$140.00
2/1/2024Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$120.00 ➝ $140.00
1/23/2024Morgan StanleyInitiated CoverageOverweight$120.00
1/16/2024UBS GroupInitiated CoverageNeutral
1/12/2024Cantor FitzgeraldReiterated RatingOverweight
12/18/2023Cantor FitzgeraldReiterated RatingOverweight
12/4/2023TD CowenBoost TargetOutperform ➝ Outperform$105.00 ➝ $115.00
12/1/2023Cantor FitzgeraldInitiated CoverageOverweight$120.00
10/2/2023ArgusInitiated CoverageBuy$110.00
8/11/2023DNB MarketsDowngradeBuy ➝ Hold
7/14/2023HSBCInitiated CoverageBuy
4/13/2023Credit Suisse GroupUpgradeNeutral ➝ Outperform
12/12/2022CowenBoost Target$32.50 ➝ $36.25
12/12/2022CowenBoost Target$32.50 ➝ $36.25
11/4/2022Credit Suisse GroupBoost Target205.00 ➝ 215.00
9/29/2022Oddo BhfUpgradeNeutral ➝ Outperform
7/15/2022Morgan StanleyUpgradeEqual Weight ➝ Overweight
6/28/2022UBS GroupDowngradeNeutral ➝ Sell
6/7/2022JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight
5/31/2022GuggenheimUpgradeNeutral ➝ Buy
5/5/2022Bryan, Garnier & CoUpgradeSell ➝ Neutral
5/4/2022Deutsche Bank AktiengesellschaftBoost Target212.50 ➝ 225.00
4/25/2022CowenUpgradeMarket Perform ➝ Outperform$32.50
4/25/2022CowenUpgradeMarket Perform ➝ Outperform
4/19/2022Berenberg BankBoost TargetHold ➝ Hold146.25 ➝ 195.00
4/12/2022Morgan StanleyUpgradeUnderweight ➝ Equal Weight
3/16/2022Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy
3/2/2022CitigroupUpgradeNeutral ➝ Buy
3/1/2022Berenberg BankBoost TargetHold ➝ Hold132.50 ➝ 146.25
2/28/2022Stifel NicolausInitiated CoverageBuy
2/3/2022DanskeUpgradeHold ➝ Buy
1/25/2022Liberum CapitalDowngradeHold ➝ Sell
12/20/2021CitigroupDowngradeBuy ➝ Neutral
12/20/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral
12/20/2021DanskeDowngradeBuy ➝ Hold
12/17/2021Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold
11/11/2021UBS GroupReiterated RatingNeutral
11/4/2021BarclaysReiterated RatingOverweight
11/4/2021Credit Suisse GroupReiterated RatingNeutral
11/4/2021JPMorgan Chase & Co.Reiterated RatingOverweight
11/3/2021Bryan, Garnier & CoDowngradeBuy ➝ Sell148.00
11/2/2021Morgan StanleyReiterated RatingUnderweight
11/1/2021Deutsche Bank AktiengesellschaftReiterated RatingBuy
10/29/2021DNB MarketsDowngradeBuy ➝ Hold
10/18/2021SEB EquitiesUpgradeHold ➝ Buy
9/3/2021Berenberg BankReiterated RatingHold
8/23/2021Credit Suisse GroupReiterated RatingNeutral
8/23/2021CitigroupReiterated RatingBuy
8/17/2021UBS GroupReiterated RatingNeutral
8/11/2021Morgan StanleyReiterated RatingUnderweight
8/6/2021JPMorgan Chase & Co.Reiterated RatingOverweight
8/5/2021BarclaysReiterated RatingOverweight
8/5/2021Bank of AmericaUpgradeNeutral ➝ Buy
8/5/2021DNB MarketsUpgradeHold ➝ Buy
8/3/2021Deutsche Bank AktiengesellschaftReiterated RatingBuy
7/19/2021BarclaysReiterated RatingOverweight
7/15/2021Deutsche Bank AktiengesellschaftReiterated RatingBuy
2/11/2021UBS GroupReiterated RatingNeutral
2/4/2021BarclaysReiterated RatingOverweight
1/20/2021Credit Suisse GroupDowngradeOutperform ➝ Neutral
1/15/2021Deutsche Bank AktiengesellschaftInitiated CoverageBuy
(Data available from 12/4/2020 forward)

News Sentiment Rating

0.60 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 58 very positive mentions
  • 26 positive mentions
  • 20 negative mentions
  • 3 very negative mentions
Mentions as of
11/4/2025
  • 171 very positive mentions
  • 91 positive mentions
  • 66 negative mentions
  • 8 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 171 very positive mentions
  • 91 positive mentions
  • 66 negative mentions
  • 8 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Novo Nordisk A/S logo
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Read More

Today's Range

Now: $47.99
Low: $47.37
High: $48.24

50 Day Range

MA: $51.94
Low: $44.99
High: $59.68

52 Week Range

Now: $47.99
Low: $43.08
High: $112.52

Volume

18,437,415 shs

Average Volume

20,787,550 shs

Market Capitalization

$214.28 billion

P/E Ratio

13.95

Dividend Yield

1.73%

Beta

0.67

Frequently Asked Questions

What sell-side analysts currently cover shares of Novo Nordisk A/S?

The following Wall Street analysts have issued stock ratings on Novo Nordisk A/S in the last year: Barclays PLC, Berenberg Bank, BMO Capital Markets, BNP Paribas, BNP Paribas Exane, Dbs Bank, Guggenheim, Hsbc Global Res, HSBC Holdings plc, Jefferies Financial Group Inc., Kepler Capital Markets, Morgan Stanley, Rothschild & Co Redburn, Rothschild Redb, Sanford C. Bernstein, Stifel Nicolaus, TD Cowen, The Goldman Sachs Group, Inc., UBS Group AG, Wall Street Zen, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for NVO.

What is the current price target for Novo Nordisk A/S?

0 Wall Street analysts have set twelve-month price targets for Novo Nordisk A/S in the last year. Their average twelve-month price target is $56.00, suggesting a possible upside of 16.7%. HSBC Holdings plc has the highest price target set, predicting NVO will reach $70.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $42.00 for Novo Nordisk A/S in the next year.
View the latest price targets for NVO.

What is the current consensus analyst rating for Novo Nordisk A/S?

Novo Nordisk A/S currently has 2 sell ratings, 12 hold ratings, 6 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in NVO, but not buy more shares or sell existing shares.
View the latest ratings for NVO.

What other companies compete with Novo Nordisk A/S?

Other companies that are similar to Novo Nordisk A/S include AstraZeneca, Novartis, Sanofi, GSK and argenex. Learn More about companies similar to Novo Nordisk A/S.

How do I contact Novo Nordisk A/S's investor relations team?

Novo Nordisk A/S's physical mailing address is Novo Alle, Bagsvaerd G7, 2880. The company's listed phone number is (454) 444-8888 and its investor relations email address is [email protected]. The official website for Novo Nordisk A/S is www.novonordisk.com. Learn More about contacing Novo Nordisk A/S investor relations.